CTIS2022-502275-39-00进行中（未招募）1 期
OMC04
Oslo University Hospital Hf0 个研究点目标入组 20 人开始时间: 2022年10月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic DermatitisAtopic DermatitisCTIS2022-502997-18-00Bristol-Myers Squibb Services Unlimited Company64
进行中（未招募）
1 期
A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy.EpilepsyCTIS2022-502638-17-00Trevena Inc.24
招募中
1 期
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with pembrolizumab in patients with advanced solid tumorsSelected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).CTIS2024-514746-36-00Oncomatryx Biopharma S.L.120
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
招募中
1 期
A study in women with overweight or obesity to test whether different doses of BI 456906 influence the amount of a contraceptive in the bloodpharmacokinetic trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2022-503146-53-00Boehringer Ingelheim International GmbH24